

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Liraglutide for managing overweight and obesity

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

<p>During consultation, several comments highlighted that differences in the BMI and waist circumference cut-offs associated with increased risk of ill health depends on ethnicity.</p>
--

<p>Another comment highlighted that people with significant mental health illness and learning disabilities are subgroups that are particularly difficult to treat, and that consideration needs to be given to ensure they have equality in access to treatment.</p>

<p>Another comment highlighted that incidence of overweight and obesity may depend on socio-economic status.</p>
--

<p>One comment said that the lack of available effective treatment options for the management of obesity means there may be inequity in access to treatment.</p>
--

<p>The CHTE equalities expert group advised that people with obesity may be covered under the disability provision of the equality act.</p>

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

<p>The CHTE equalities expert advice group advised that:</p>
--

- | |
|--|
| <ul style="list-style-type: none">• the recommendations should explain that appropriate adjustment to BMI criteria should be made for older people and ethnic minorities• with regards to the scope and the Committee, age and ethnicity should be considered so that the obese and overweight population are |
|--|

included (i.e. a study in an Asian population that is obese but with a lower BMI than 30 is not excluded).

- analyses and recommendations should not be stratified based on age or ethnicity unless there is strong evidence to suggest the effectiveness of the drug would be different in these groups.

The committee will also need to consider how any recommendations it makes may have a differential impact on people with mental illness or learning disability and also the relevance of ethnicity when considering BMI thresholds.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The background of the scope highlights that some ethnic groups may be at increased risk of some ill health conditions at lower BMI than people of European family origin.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): ...Janet Robertson.....

Date: 10 April 2019